China Shineway Pharmaceutical Group Limited (C1S) — Net Asset Quality Index
China Shineway Pharmaceutical Group Limited (C1S) has a Net Asset Quality Index of 74.8% as of December 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of €10.78 Billion minus total liabilities of €2.72 Billion yields net assets of €8.06 Billion. A higher index indicates a stronger, lower-leverage balance sheet. See C1S days of operational coverage to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
China Shineway Pharmaceutical Group Limited Net Asset Quality Index Over Time (2013–2025)
This chart shows how China Shineway Pharmaceutical Group Limited's Net Asset Quality Index has evolved across 13 annual periods from 2013 to 2025. As of December 2025, the index stands at 74.8%, representing net assets of €8.06 Billion against total assets of €10.78 Billion EUR. Explore how efficiently does China Shineway Pharmaceutical Group Limi generate cash to assess how effectively this company generates cash.
Annual Net Asset Quality Index for China Shineway Pharmaceutical Group Limited (2013–2025)
The table below presents the year-by-year Net Asset Quality Index for China Shineway Pharmaceutical Group Limited from 2013 to 2025, covering 13 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see China Shineway Pharmaceutical Group Limi (C1S) total market value.
| Year | Quality Index | Net Assets (EUR) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 74.8% | €8.06 Billion | €10.78 Billion | €2.72 Billion | ▲ +0.4 pp |
| 2024 | 74.4% | €7.47 Billion | €10.04 Billion | €2.57 Billion | ▲ +0.9 pp |
| 2023 | 73.5% | €7.03 Billion | €9.57 Billion | €2.54 Billion | ▼ -4.1 pp |
| 2022 | 77.5% | €6.38 Billion | €8.23 Billion | €1.85 Billion | ▼ -4.4 pp |
| 2021 | 81.9% | €5.90 Billion | €7.20 Billion | €1.30 Billion | ▲ +1.6 pp |
| 2020 | 80.3% | €5.79 Billion | €7.21 Billion | €1.42 Billion | ▼ -0.7 pp |
| 2019 | 81.0% | €5.78 Billion | €7.13 Billion | €1.35 Billion | ▼ -4.6 pp |
| 2018 | 85.7% | €5.77 Billion | €6.73 Billion | €966.01 Million | ▼ -1.7 pp |
| 2017 | 87.3% | €5.82 Billion | €6.67 Billion | €844.16 Million | ▲ +0.3 pp |
| 2016 | 87.0% | €5.63 Billion | €6.47 Billion | €838.59 Million | ▲ +1.0 pp |
| 2015 | 86.1% | €5.30 Billion | €6.15 Billion | €857.13 Million | ▲ +3.2 pp |
| 2014 | 82.8% | €4.89 Billion | €5.91 Billion | €1.01 Billion | ▲ +5.6 pp |
| 2013 | 77.2% | €4.43 Billion | €5.74 Billion | €1.31 Billion | — |